Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Artivion (AORT)
NYSE:AORT
Holding AORT?
Track your performance easily
AORT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.16 - $29.24
Previous Close$25.25
Volume253.21K
Average Volume (3M)253.90K
Market Cap
$1.06B
Enterprise Value$1.36B
Total Cash (Recent Filing)$55.02M
Total Debt (Recent Filing)$362.01M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Oct 31, 2024EPS Estimate
-$0.06Last Dividend Ex-Date
Dec 09, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding41,893,465
10 Day Avg. Volume193,669
30 Day Avg. Volume253,899
Standard Deviation0.14
R-Squared0.41
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)3.52
Price to Sales (P/S)2.70
Price to Cash Flow (P/CF)41.50
P/FCF Ratio21.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.62
Enterprise Value/Gross Profit5.96
Enterprise Value/Ebitda25.13
Forecast
1Y Price Target
$30.32Price Target Upside20.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Artivion News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPositive full data from the PERSEVERE study of AMDS presented at a significant medical conference showed a substantial reduction in mortality and adverse events, bolstering confidence in its potential FDA approval.
Executive AppointmentLance Berry is set to take over as CFO, bringing a positive reputation from his tenure at Wright Medical, which may instill investor confidence in the company's future financial leadership.
GuidanceThe Company provided revenue guidance for the next year that exceeds market expectations, indicating a strong financial outlook.
Bears Say
Executive Team ChangeCFO Ashley Lee, having steered the company through significant growth, is set to retire, potentially leading to uncertainties in financial leadership.
Financial ForecastAdjusted EBITDA guidance for the next year falls short of market analysts' expectations.
Financial PerformanceAnalysts express concern as the company's projected EBITDA does not align with the expected market consensus.
---
Ownership Overview
18.58% Insiders
25.55% Mutual Funds
45.86% Other Institutional Investors
10.01% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AORT FAQ
What was Artivion’s price range in the past 12 months?
Artivion lowest stock price was $12.16 and its highest was $29.24 in the past 12 months.
What is Artivion’s market cap?
Currently, no data Available
When is Artivion’s upcoming earnings report date?
Artivion’s upcoming earnings report date is Oct 31, 2024 which is in 47 days.
How were Artivion’s earnings last quarter?
Artivion released its earnings results on Aug 08, 2024. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.04.
Is Artivion overvalued?
According to Wall Street analysts Artivion’s price is currently Undervalued.
Does Artivion pay dividends?
Artivion pays a Quarterly dividend of $0.03 which represents an annual dividend yield of N/A. See more information on Artivion dividends here
What is Artivion’s EPS estimate?
Artivion’s EPS estimate is -$0.06.
How many shares outstanding does Artivion have?
Artivion has 41,893,463 shares outstanding.
What happened to Artivion’s price movement after its last earnings report?
Artivion reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went down -1.895%.
Which hedge fund is a major shareholder of Artivion?
Among the largest hedge funds holding Artivion’s share is Perceptive Advisors LLC. It holds Artivion’s shares valued at 72M.
---
Artivion Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.32 (20.08% Upside)
$30.32 (20.08% Upside)
Blogger Sentiment
Bullish
AORT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 37.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $626.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.8%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.70%
12-Months-Change
Fundamentals
Return on Equity
-2.88%
Trailing 12-Months
Asset Growth
1.50%
Trailing 12-Months
Company Description
Artivion
CryoLife, Inc. engages in the manufacture, process and distribution of medical devices. It operates through the following segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of BioGlue; JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PerClot and PhotoFix. The Preservation Services segment focuses on external services revenues from the preservation of cardiac and vascular tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.
---
AORT Company Deck
---
AORT Earnings Call
Q2 2024
0:00 / 0:00
---
AORT Stock 12 Month Forecast
Average Price Target
$30.32
▲(20.08% Upside)
Technical Analysis
Best Analysts Covering AORT
1 Year
1 Year Success Rate
21/33 ratings generated profit
1 Year Average Return
+11.62%
reiterated a buy rating last month
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +11.62% per trade.
---